Biotest Pharmaceuticals names new chief executive

Jordan Siegel is promoted from chief financial officer

Jordan Siegel will become chief executive of Biotest Pharmaceuticals Corporation (BPC), a wholly owned subsidiary of Biotest AG of Dreieich, Germany, on 1 May.

BPC’s interim chief executive, Georg Floss, will return to Germany on 30 April to assume the role of global head of operations at Biotest AG.

Siegel has been BPC’s senior vice president, finance and chief financial officer since its inception in 2007.

BPC researches, develops and manufactures biotherapeutic products for immunology and haematology. The firm is a leader in the collection of source plasma and is currently involved in the development of plasma protein products in the field of Primary Immune Deficiency (PID) and various hyperimmune (IG) products. It owns and manages 12 plasmapherisis centres across the US and a manufacturing facility in Boca Raton, Florida.

You may also like

Manufacturing

Roquette opens pharmaceutical innovation centre in Brazil

The Health & Pharma Solutions facility in São Paolo offers state-of-the-art laboratories for customers, with the Northeast Center for Strategic Technologies partnering with Roquette to empower young women to pursue careers in science through the Futuras Cientistas programme at the facility
Manufacturing

Samsung Bioepis and Phrontline join forces to advance best-in-class antibody-drug conjugate therapeutics for solid tumours

The pair will co-develop two investigational ADC assets directed against targets expressed in a broad range of cancers, adding a new class of bispecific and dual-payload ADC therapeutics to Samsung Bioepis' oncology portfolio
Research & Development

Amphista Therapeutics nominates first clinical candidate AMX-883, a novel Targeted Glue degrader for acute myeloid leukaemia

AMX-883, an orally available BRD9 degrader developed using Amphista’s Eclipsys platform, shows potent preclinical efficacy and a distinct DCAF16-based mechanism of action, paving the way for first-in-human trials in 2026
Pharmaceutical

Boehringer Ingelheim adds antibody-based cancer drug from AimedBio to its portfolio

The two have signed a licence agreement, which will advance Boehringer’s expanding antibody-drug conjugate (ADC) portfolio with the new asset expected to enter first-in-human studies next year
Microbiology

Balchem to showcase new line of probiotic stabilising excipients at SupplySide Global

The company will debut its new excipient portfolio, StabiliPro, at SupplySide Global 2025 in Las Vegas
Pharmaceutical

ProSpecBio launches CHO cell-derived Activin-A recombinant protein to advance inflammation and brain injury research

ProSpecBio has introduced a highly purified, CHO cell-derived recombinant Activin-A protein, enabling researchers worldwide to explore its therapeutic potential in inflammation, brain injury and regenerative medicine
Pharmaceutical

Asahi Kasei expands Sonanos portfolio with next-generation excipients for injectable drug formulation

Asahi Kasei has introduced two new speciality grades in its Sonanos excipient line designed to enhance sustained release and solubility in injectable drugs and plans GMP-compliant production by 2027
Subscribe now